Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buprenorphine for Severe Suicidal Ideation in Depression
NCT03646058Phase 3Recruiting
- Sponsor
- CHU Nîmes
- Start
- Oct 2021
- Primary completion
- Oct 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of buprenorphine in suicidal ideation (3 arms), sponsored by CHU Nîmes. Primary endpoint: Changes in Beck Scale for Suicidal Ideation (SSI) scores. Started Oct 2021; status: recruiting.
02
Drugs
buprenorphine
03
Conditions
suicidal ideation
Beyond the preview
Go deeper on NCT03646058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03646058.